Plain-English translation of NCT07630714 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called anifrolumab to see if it helps children and teens with systemic lupus erythematosus (SLE)—a disease where the immune system attacks the body's own tissues. The medication is given as a subcutaneous injection (under the skin) using a pre-filled syringe. Researchers want to learn how safe the medication is, how the body processes it, and whether it helps reduce lupus symptoms in young patients.
Lupus in children can be serious and hard to treat with current options. This medication works differently than standard treatments by targeting a specific part of the immune system, and this trial will help doctors understand if it's safe and effective for young patients.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic for a screening period lasting up to 35 days, then receive the medication as subcutaneous injections over 12 weeks in the main treatment phase. Depending on how you respond, there may be a 12-week adjustment period, and you may be offered an optional extension of up to 40 weeks. After treatment ends, you would have a 12-week safety follow-up period with additional clinic visits. Blood tests and assessments of your lupus disease activity would happen throughout the trial.
AI-generated summary from trial data · Oct 2, 2026 · Not medical advice
Australia
Belgium